Answers are grounded in this paper and cite their sources.
Molecular docking shows beta-sitosterol and astaxanthin enhance COX-2 binding affinity, suggesting a potential safer anti-inflammatory therapy.
Cyclooxygenase enzymes, mainly COX-1 and COX-2, have been shown to contribute to the regulation of inflammation, pain, and physiological homeostasis, positioning them as critical targets for the development of novel anti-inflammatory therapies. Although NSAIDs have proven their efficacy in COX inhibition, their adverse effects have limited their use, highlighting a research gap that necessitates further exploration of natural compounds, such as beta-sitosterol (BS) and astaxanthin (AXT), as potentially safer, selective COX modulators. This study aimed to explore the potential synergistic effects of BS-AXT combination in modulating COX enzymes through molecular docking to discover their combined activity as safer, natural anti-inflammatory agents. Docking results revealed that the BS-AXT combination significantly enhanced the binding affinity of BS to COX-2, improving from -7.5424 kcal/mol (alone) to -9.2033 kcal/mol in the combination form, indicating a potential synergistic interaction. Consistent with previous docking studies, BS and AXT demonstrated similar binding behaviors, dominated by hydrophobic interactions, particularly with key nonpolar residues within the COX-2 active site. In conclusion, the docking results suggest that the BS-AXT combination could be a natural COX-2 selective inhibitor, supporting the need for further studies to confirm its effectiveness and safety.
No takes yet. Share an insight, caveat, or question.
Rahim et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: